Advertising Driven Press Release Distribution
Advertising Driven Press Release Distribution
Involved pharmaceutical companies in the Thrombotic Thrombocytopenic Purpura market are Takeda, Lee’s Pharmaceutical and others.
DelveInsight’s Thrombotic Thrombocytopenic Purpura Pipeline Report provides a disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. This report gives a detailed clinical and non-clinical stage products analysis. The TTP report also highlights the unmet needs with respect to the development of Thrombotic Thrombocytopenic Purpura.
Some of the key highlights from the Thrombotic Thrombocytopenic Purpura Pipeline Report-
Request for Sample @ Thrombotic Thrombocytopenic Purpura Pipeline Insight
Thrombotic Thrombocytopenic Purpura (TTP) is a rare, life-threatening thrombotic microangiopathy characterized by microangiopathic hemolytic anaemia, severe thrombocytopenia, and organ ischemia with profound thrombocytopenia. TTP is characterized by a severe deficiency in ADAMTS13 (a disintegrin & metalloprotease with thrombospondin type 1 repeats, member 13), the specific von Willebrand factor (vWf)-cleaving protease.
Thrombotic Thrombocytopenic Purpura Pipeline Emerging Therapies: Drug Profile
BAX 930/ TAK755/SHP655 (Shire) is a fully glycosylated recombinant human ADAMTS-13 protein that restores the missing enzyme in a patient’s blood without the risk for complications for human-donor plasma.
The FDA has been granted fast track designation to BAX930 for the therapy of acute episodes of hereditary TTP in patients with a constitutional deficiency of the von Willebrand factor-cleaving (VWF) protease ADAMTS13.
Currently, the drug is in phase III trial, which aims to assess the safety & efficacy of BAX 930 in the prevention & treatment of acute episodes of thrombotic thrombocytopenic purpura in participants with severe congenital deficiency of ADAMTS13.
Anfibatide (Lee’s Pharmaceutical) is a snake venom-derived protein that acts as a platelet glycoprotein Ib antagonist. It is in Phase II studies being evaluated as adjuvant therapy for plasma exchange in patients with acquired TTP. The drug has received an orphan designation for TTP from the US FDA.
Know More Information @ Thrombotic Thrombocytopenic Purpura Pipeline Drugs
Key Pipeline Therapies along with Companies
Thrombotic Thrombocytopenic Purpura Therapeutic Assessment
By Product Type
By Route of Administration
By Molecule Type
By Mechanism of Action
By Stage and Route of Administration
By Stage and Product Type
Contact here for more information @ Thrombotic Thrombocytopenic Purpura Pipeline Assessment
Scope of the Report
Table of content
|2||Thrombotic Thrombocytopenic Purpura|
|3||Thrombotic Thrombocytopenic Purpura Current Treatment Patterns|
|4||Thrombotic Thrombocytopenic Purpura DelveInsight’s Analytical Perspective|
|6||TTP Late Stage Products (Phase-III)|
|7||TTP mid Stage Products (Phase-II)|
|8||Thrombotic Thrombocytopenic Purpura Early Stage Products (Phase-I)|
|9||Pre-clinical Products and Discovery Stage Products|
|12||TTP Discontinued Products|
|13||TTP Product Profiles|
|14||Thrombotic Thrombocytopenic Purpura Key Companies|
|15||TTP Key Products|
|16||Dormant and Discontinued Products|
|17||Thrombotic Thrombocytopenic Purpura Unmet Needs|
|18||Thrombotic Thrombocytopenic Purpura Future Perspectives|
|19||Thrombotic Thrombocytopenic Purpura Analyst Review|
Know more of what’s covered in the Thrombotic Thrombocytopenic Purpura Pipeline Assessment report
Key Questions Answered in the Thrombotic Thrombocytopenic Purpura report
Request for a Webex demo @ Thrombotic Thrombocytopenic Purpura Pipeline and get a walk-through of our report
Thrombotic Thrombocytopenic Purpura Market
DelveInsight’s Thrombotic Thrombocytopenic Purpura Market Insights, Epidemiology and Market Forecast 2030 report.
Thrombotic Thrombocytopenic Purpura Epidemiology
DelveInsight’s Thrombotic Thrombocytopenic Purpura – Epidemiology Forecast 2030 report
Thrombotic Thrombocytopenic Purpura Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020
Thrombotic Thrombocytopenic Purpura Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020″ report
DelveInsight’ s Beta-thalassemia Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’ s Hemophilia B – Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’ s Hemophilia – Market Insights, Epidemiology and Market Forecast – 2030 report.
Hypofibrinogenemia Market Insights, Epidemiology, & Market Forecast-2030 report
Visit on our blog section-
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.
Bladder Scanners Market Expected to Expand at an Impressive Rate by 2026 Owing to the Initative by Key Companies such as C. R. Bard, Verathon, dBMEDx, Vitacon, LABORIE, MCube, Caresono, MEDA, Prometheus, Roper, SRS Medical, and SIFSOF
Non-Small Cell Lung Cancer Pipeline Insights: 100+ Key Pharma Players and 100+ Therapies to Look Out for in the Non-Small Cell Lung Cancer Pipeline Landscape
Meniere’s Disease (MD) Epidemiology: A Deeper Insights into the Patient Population, Medical Practices, Disease Risk, Burden, Factors Driving Population Growth, and Forecasted Epidemiology Till 2030
Neuromodulation Devices Market to Witness Upsurge in Growth During the Forecast Period 2026 | Key Companies in the Market Includes- Micron Medical, Boston Scientific Corporation, Abbott, SensArs, SunMed, Neuronetics, Neuros Medical, and Others
The Ongoing Clinical Studies and Trials for Myelodysplastic Syndrome are Expected to Provide a New Dimension to MDS Care in the Coming Years.